Tirzepatide enhances liver structural integrity by promoting mitochondrial dynamics and mitophagy via PINK1/PRKN and SIRT3/NRF2 pathways in an obese-diabetic-menopausal mouse model.
Marcondes-de-Castro. Ilitch A IA; Marinho. Thatiany S TS; Aguila. Marcia B MB; Mandarim-de-Lacerda. Carlos A CA
Key Findings
- Tirzepide prevented fat buildup, swelling and damage to liver mitochondria in obese‑diabetic, menopausal mice.
- It lowered the activity of genes that drive autophagy and mitophagy (Ulk3, Atg5, Atg7, PINK1, PRKN) while increasing genes for mitochondrial creation and antioxidant protection (PPARGC1A, TFAM, SOD2, SIRT3, NRF2).
- Markers of endoplasmic reticulum stress and mitochondrial fission were reduced, and fusion proteins (MFN1, MFN2) were restored, indicating overall better cellular health.
Practical Outcomes
- For biohackers interested in liver health, tirzepide may offer a dual benefit of weight loss and protection against fatty‑liver damage by improving mitochondrial function. While the mouse data are promising, human dosing and safety for liver‑specific goals are not yet established, so any off‑label use should be approached cautiously and preferably under medical supervision.
Summary
In a mouse study that mimics obesity, type‑2 diabetes and menopause, daily tirzepatide kept the liver’s structure intact and helped the tiny power plants inside liver cells (mitochondria) stay healthy. It did this by balancing the processes that build, break down, and clean up mitochondria, and by boosting antioxidant defenses.
Abstract
The effects on hepatic mitochondrial structure, mitophagy, and cellular homeostasis were investigated when treated with Tirzepatide (Tzp), a dual GIP/GLP-1 receptor agonist, in a mouse model combining obesity, type 2 diabetes, and menopause-conditions that collectively exacerbate metabolic dysfunction-associated steatotic liver disease (MASLD). Female C57BL/6 mice were fed either a control or high-fat, high-sucrose diet for 12 weeks, and half underwent bilateral ovariectomy to simulate menopause. Tzp was administered daily for four weeks. Liver tissue was evaluated for ultrastructural alterations, gene expression, and protein profiles. Untreated obese-diabetic and obese-diabetic-ovariectomized mice exhibited hepatocellular fat accumulation, mitochondrial swelling, and disorganized cristae, indicative of metabolic and oxidative stress. In contrast, Tzp-treated mice displayed preserved hepatic architecture and intact mitochondrial morphology. Tzp significantly downregulated autophagy genes (Ulk3, Atg5, Atg7) and key mitophagy regulators (PINK1, PRKN), reestablishing mitochondrial balance, primarily through the modulation of mitophagy and enhanced organelle stability. Simultaneously, it upregulated mitochondrial biogenesis markers (Ppargc1a, Tfam), antioxidant enzymes (SOD2, GR, GPX, CAT), and redox modulators (Sirt3, Nrf2), while normalizing oxidative stress-related genes (Nos1, Nox1). Tzp also mitigated endoplasmic reticulum (ER) stress by downregulating Atf4, Ddit3, and Gadd45 and rebalanced mitochondrial dynamics through the suppression of fission markers (Dnml1, Fis1) and the restoration of fusion mediators (Mfn1, Mfn2). Three-way ANOVA confirmed Tzp's broad regulatory effects on hepatic gene expression, while principal component analysis revealed clear transcriptional separation between treated and untreated groups. In conclusion, these findings demonstrate that Tzp preserves liver ultrastructure and restores mitochondrial dynamics, supporting its therapeutic potential in MASLD and hormone-related metabolic disorders.
Study Information
pubmed
2025
2025-09-17T00:00:00.000Z
10.1016/j.tice.2025.103146
1
47